Skip to main content
Top
Published in: Cardiology and Therapy 2/2020

Open Access 01-12-2020 | Hepatorenal Syndrome | Original Research

In-Hospital Outcomes of Patients with Acute Decompensated Heart Failure and Cirrhosis: An Analysis of the National Inpatient Sample

Authors: Yaser S. Khalid, Debashis Reja, Neethi R. Dasu, Herman P. Suga, Kirti N. Dasu, Lucy M. Joo

Published in: Cardiology and Therapy | Issue 2/2020

Login to get access

Abstract

Introduction

Heart failure increases morbidity and mortality in patients admitted for cirrhosis. Our objective was to determine if patients with acute decompensated heart failure (ADHF) and cirrhosis would have increased mortality, hospital length of stay (LOS), and total hospital charges compared to patients with only ADHF. There is also a paucity of data regarding the influence of gender, race, ethnicity, insurance, and cirrhosis-related complications on mortality, hospital length of stay, and total hospitalization charges. In this study, we aim to identify risk factors in a national population cohort from 2016.

Methods

All patients above 18 years old with cirrhosis and ADHF admitted in 2016 were identified from the Nationwide Inpatient Sample (NIS). Multivariate regression analysis was used to estimate the odds ratio of in-hospital mortality, average length of stay (LOS), and total hospital charges after adjusting for the following factors: age, gender, race, Charlson and Elixhauser scores, primary insurance payer status, hospital type, hospital bed size, hospital region, and hospital teaching status. Statistical analysis was performed by using the survey procedures function in the statistical analysis system (SAS) software. Statistical significance was defined by the two-sided t-test with a p value < 0.05.

Results

The overall sample contained 363,050 patients. A total of 355,455 patients were admitted with ADHF and 2% of these patients had concomitant cirrhosis (n = 7595) in 2016. The total mortality rate was 3.4%, hospital LOS was 6.6 days (with a median of 6.5 days), and the mean total hospital charge was $63,120.20. Patients with both ADHF and cirrhosis compared to patients without ADHF had increased mortality, hospital LOS, and cirrhosis-related complications.

Conclusions

As the incidence and prevalence of ADHF and cirrhosis increases worldwide, we urge the medical community to increase surveillance of patients with both diseases and perform rigorous cardiovascular risk assessments as well to improve patient outcomes.
Literature
1.
go back to reference Allen LA, Smoyer Tomic KE, Wilson KL, Smith DM, Agodoa I. The inpatient experience and predictors of length of stay for patients hospitalized with systolic heart failure: comparison by commercial, Medicaid, and Medicare payer type. J Med Econ. 2013;16(1):43–544.CrossRefPubMed Allen LA, Smoyer Tomic KE, Wilson KL, Smith DM, Agodoa I. The inpatient experience and predictors of length of stay for patients hospitalized with systolic heart failure: comparison by commercial, Medicaid, and Medicare payer type. J Med Econ. 2013;16(1):43–544.CrossRefPubMed
2.
go back to reference Mirkin KA, Enomoto LM, Caputo GM, Hollenbeak CS. Risk factors for 30-day readmission in patients with congestive heart failure. Heart Lung. 2017;46(5):357–62.CrossRefPubMed Mirkin KA, Enomoto LM, Caputo GM, Hollenbeak CS. Risk factors for 30-day readmission in patients with congestive heart failure. Heart Lung. 2017;46(5):357–62.CrossRefPubMed
4.
go back to reference Chirapongsathorn S, Poovorawan K, Soonthornworasiri N, Pan-ngum W, Phaosawasdi K, Treeprasertsuk S. Thirty-day readmission and cost analysis in patients with cirrhosis: a nationwide population-based data. Hepatol Commun. 2020;4(3):453–60.CrossRefPubMedPubMedCentral Chirapongsathorn S, Poovorawan K, Soonthornworasiri N, Pan-ngum W, Phaosawasdi K, Treeprasertsuk S. Thirty-day readmission and cost analysis in patients with cirrhosis: a nationwide population-based data. Hepatol Commun. 2020;4(3):453–60.CrossRefPubMedPubMedCentral
5.
go back to reference Fede G, Privitera G, Tomaselli T, Spadaro L, Purrello F. Cardiovascular dysfunction in patients with liver cirrhosis. Ann Gastroenterol Q Publ Hell Soc Gastroenterol. 2015;28(1):31–40. Fede G, Privitera G, Tomaselli T, Spadaro L, Purrello F. Cardiovascular dysfunction in patients with liver cirrhosis. Ann Gastroenterol Q Publ Hell Soc Gastroenterol. 2015;28(1):31–40.
7.
go back to reference Sud M, Yu B, Wijeysundera HC, Austin PC, Ko DT, Braga J, et al. Associations between short or long length of stay and 30-day readmission and mortality in hospitalized patients with heart failure. JACC Heart Fail. 2017;5(8):578–88.CrossRefPubMed Sud M, Yu B, Wijeysundera HC, Austin PC, Ko DT, Braga J, et al. Associations between short or long length of stay and 30-day readmission and mortality in hospitalized patients with heart failure. JACC Heart Fail. 2017;5(8):578–88.CrossRefPubMed
8.
go back to reference Pandey A, Omar W, Ayers C, LaMonte M, Klein L, Allen N, et al. Sex and race differences in lifetime risk of heart failure with preserved ejection fraction and heart failure with reduced ejection fraction. Circulation. 2018;137(17):1814–23.CrossRefPubMedPubMedCentral Pandey A, Omar W, Ayers C, LaMonte M, Klein L, Allen N, et al. Sex and race differences in lifetime risk of heart failure with preserved ejection fraction and heart failure with reduced ejection fraction. Circulation. 2018;137(17):1814–23.CrossRefPubMedPubMedCentral
9.
go back to reference Desai AP, Mohan P, Nokes B, Sheth D, Knapp S, Boustani M, et al. Increasing economic burden in hospitalized patients with cirrhosis: analysis of a national database. Clin Transl Gastroenterol. 2019;10(7):e00062.CrossRefPubMedPubMedCentral Desai AP, Mohan P, Nokes B, Sheth D, Knapp S, Boustani M, et al. Increasing economic burden in hospitalized patients with cirrhosis: analysis of a national database. Clin Transl Gastroenterol. 2019;10(7):e00062.CrossRefPubMedPubMedCentral
10.
go back to reference Joshi AV, D’Souza AO, Madhavan SS. Differences in hospital length-of-stay, charges, and mortality in congestive heart failure patients. Congest Heart Fail. 2004;10(2):76–84.CrossRefPubMed Joshi AV, D’Souza AO, Madhavan SS. Differences in hospital length-of-stay, charges, and mortality in congestive heart failure patients. Congest Heart Fail. 2004;10(2):76–84.CrossRefPubMed
11.
go back to reference Bansal S, Lindenfeld J, Schrier RW. Sodium retention in heart failure and cirrhosis: potential role of natriuretic doses of mineralocorticoid antagonist? Circ Heart Fail. 2009;2(4):370–6.CrossRefPubMed Bansal S, Lindenfeld J, Schrier RW. Sodium retention in heart failure and cirrhosis: potential role of natriuretic doses of mineralocorticoid antagonist? Circ Heart Fail. 2009;2(4):370–6.CrossRefPubMed
12.
go back to reference Schrier RW. Decreased effective blood volume in edematous disorders: what does this mean? J Am Soc Nephrol. 2007;18(7):2028–31.CrossRefPubMed Schrier RW. Decreased effective blood volume in edematous disorders: what does this mean? J Am Soc Nephrol. 2007;18(7):2028–31.CrossRefPubMed
13.
14.
go back to reference Hsu R-B, Chang C-I, Lin F-Y, Chou N-K, Chi N-H, Wang S-S, et al. Heart transplantation in patients with liver cirrhosis. Eur J Cardiothorac Surg. 2008;34(2):307–12.CrossRefPubMed Hsu R-B, Chang C-I, Lin F-Y, Chou N-K, Chi N-H, Wang S-S, et al. Heart transplantation in patients with liver cirrhosis. Eur J Cardiothorac Surg. 2008;34(2):307–12.CrossRefPubMed
15.
go back to reference Vivo RP, Krim SR, Cevik C, Witteles RM. Heart failure in Hispanics. J Am Coll Cardiol. 2009;53(14):1167–75.CrossRefPubMed Vivo RP, Krim SR, Cevik C, Witteles RM. Heart failure in Hispanics. J Am Coll Cardiol. 2009;53(14):1167–75.CrossRefPubMed
17.
go back to reference Kim D, Li AA, Perumpail RB, Cholankeril G, Gonzalez SA, Kim W, et al. Disparate trends in mortality of etiology-specific chronic liver disease among Hispanic subpopulations. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2019;17(8):1607–1615.e2. Kim D, Li AA, Perumpail RB, Cholankeril G, Gonzalez SA, Kim W, et al. Disparate trends in mortality of etiology-specific chronic liver disease among Hispanic subpopulations. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2019;17(8):1607–1615.e2.
18.
go back to reference Powell EE, Skoien R, Rahman T, Clark PJ, O’Beirne J, Hartel G, et al. Increasing hospitalization rates for cirrhosis: overrepresentation of disadvantaged Australians. EClinicalMedicine. 2019;11:44–53.CrossRefPubMedPubMedCentral Powell EE, Skoien R, Rahman T, Clark PJ, O’Beirne J, Hartel G, et al. Increasing hospitalization rates for cirrhosis: overrepresentation of disadvantaged Australians. EClinicalMedicine. 2019;11:44–53.CrossRefPubMedPubMedCentral
19.
go back to reference Krill T, Brown G, Weideman RA, Cipher DJ, Spechler SJ, Brilakis E, et al. Patients with cirrhosis who have coronary artery disease treated with cardiac stents have high rates of gastrointestinal bleeding, but no increased mortality. Aliment Pharmacol Ther. 2017;46(2):183–92.CrossRefPubMed Krill T, Brown G, Weideman RA, Cipher DJ, Spechler SJ, Brilakis E, et al. Patients with cirrhosis who have coronary artery disease treated with cardiac stents have high rates of gastrointestinal bleeding, but no increased mortality. Aliment Pharmacol Ther. 2017;46(2):183–92.CrossRefPubMed
Metadata
Title
In-Hospital Outcomes of Patients with Acute Decompensated Heart Failure and Cirrhosis: An Analysis of the National Inpatient Sample
Authors
Yaser S. Khalid
Debashis Reja
Neethi R. Dasu
Herman P. Suga
Kirti N. Dasu
Lucy M. Joo
Publication date
01-12-2020
Publisher
Springer Healthcare
Published in
Cardiology and Therapy / Issue 2/2020
Print ISSN: 2193-8261
Electronic ISSN: 2193-6544
DOI
https://doi.org/10.1007/s40119-020-00183-6

Other articles of this Issue 2/2020

Cardiology and Therapy 2/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine